Downregulation of DLEC1 by promoter methylation has been found in multiple cancers, including nasopharyngeal [36,37], ovarian [38], lung [39], hepatocellular [40], gastric [41], renal [42], and breast carcinomas [43], suggesting its potential as a broad TSG [44,45]. Here, DLEC1 is linked to cancer.